Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 4 ( October-December, 2016 ) > List of Articles

RESEARCH ARTICLE

Autonomic Neuromodulation through Devices for Hypertension

Atul Pathak, Benjamin Honton, Olivier Fondard, Nicolas Dumonteil, Didier Tchetche, Jean Fajadet

Citation Information : Pathak A, Honton B, Fondard O, Dumonteil N, Tchetche D, Fajadet J. Autonomic Neuromodulation through Devices for Hypertension. Hypertens J 2016; 2 (4):211-218.

DOI: 10.5005/jp-journals-10043-0058

Published Online: 00-12-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Pathak A, Honton B, Fondard O, Dumonteil N, Tchetche D, Fajadet J. Autonomic Neuromodulation through Devices for Hypertension. Hypertens J 2016;2(4):211-218.


PDF Share
  1. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 Jun;117(25):e510-526.
  2. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol 2014 May;34(3):247-256.
  3. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015 Sep;36(33):2219-2227.
  4. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens 2016 Feb;30(2):83-89.
  5. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995 Jul;311(7000):293-295.
  6. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013 Dec;31(12):2455-2461.
  7. Renal denervation for the management of resistant hypertension. Integr Blood Press Control 2015 Dec;8:57-69.
  8. Renal sympathetic denervation— a review of applications in current practice. Interv Cardiol Rev 2014;9(1):54-61.
  9. The sympathetic system and hypertension. Am J Hypertens 2000 Jun;13(6 Pt 2):99S-105S.
  10. Functional role of renal afferents. Physiol Rev 1991 Jul;71(3):659-682.
  11. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012 Nov;30(11):2230-2239.
  12. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
  13. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
  14. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014 Jul;35(26):1752-1759.
  15. Renal denervation in treatment-resistant hypertension: a reappraisal. Curr Opin Pharmacol 2015 Apr;21:48-52.
  16. SYMPLICITY HTN-3 Investigators; A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1393-1401.
  17. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015 Jan;36(4):219-227.
  18. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015 May;385(9981):1957-1965.
  19. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015 Apr;65(4):766-774.
  20. Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. Euro Intervention 2014 May;10(1):157-165.
  21. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 2014 Feb;103(2):117-124.
  22. Renal artery sympathetic denervation: observations from the UK experience. Clin Res Cardiol 2016 Jun;105(6):544-552.
  23. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre-and post-procedural comparison with the Simplicity catheter system and the Enlig HTN multi-electrode renal denervation catheter. Eur Heart J 2013 Jul;34(28):2141-2148.
  24. Multimodality intra-arterial imaging assessment of the vascular trauma induced by balloon-based and nonballoon-based renal denervation systems. Circ Cardiovasc Interv 2015 Jul;8(7):e002474.
  25. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart 2015 Jan;101(1):10-16.
  26. Renal denervation therapy for hypertension: pathways for moving development forward. J Am Soc Hypertens 2015 May;9(5):341-350.
  27. Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv 2016 Mar;9(6):589-598.
  28. A novel non-vascular system to treat resistant hypertension. Euro Intervention 2013;9(1):135-139.
  29. Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol 2015 Aug;12(8):451-463.
  30. The autonomic nervous system and hypertension. Circ Res 2014 May;114(11):1804-1814.
  31. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010 Oct;56(15):1254-1258.
  32. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009 Sep;54(3):530-536.
  33. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011 Aug;58(7):765-773.
  34. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012 Mar-Apr;6(2):152-158.
  35. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 2015 Jan;65(1):187-192.
  36. Baroreflex activation therapy in hypertension. J Hum Hypertens 2014 Aug;28(8):469-474.
  37. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 Jul-Aug;6(4):270-276.
  38. Impact of baroreflex activation therapy on renal function—a pilot study. Am J Nephrol 2014 Nov;40(4):371-380.
  39. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015 Jun;3(6):487-496.
  40. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 2013 Jan;61(1):5-13.
  41. Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. Adv Exp Med Biol 2004;551:15-21.
  42. Unilateral carotid body resection as an anti-hypertensive strategy: a proof of principle study in resistant hypertensive patients. J Hum Hypertens 2015 Oct;29(10):625.
  43. The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheter Cardiovasc Interv 2015 Apr;85(5):880-886.
  44. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014 Jul;64(1):6-12.
  45. Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation. Curr Hypertens Rep 2015 Sep;17(9):585.
  46. An arteriovenous fistula increases exercise capacity in patients with COPD. Chest 2010 Jul;138(1):52-58.
  47. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg 2014 Apr;59(4):1078-1083.
  48. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015;385(9978):1634-1641.
  49. Central arteriovenous anastomosis for hypertension: it is not all about sympathomodulation. Future Cardiol 2015 Sep;11(5):503-506.
  50. Ventrolateral medullary lesions block the antino-ciceptive and cardiovascular responses elicited by stimulating the dorsal periaqueductal grey matter in rats. Pain 1985 Mar;21(3):241-252.
  51. Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study. Brain Res 1991 Feb;541(2):206-215.
  52. Deep brain stimulation relieves refractory hypertension. Neurology 2011 Jan;76(4):405-407.
  53. Deep brain stimulation of the periaqueductal grey induces vasodilation in humans. Hypertension 2011 May;57(5):e24-25.
  54. Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. Hypertension 2014 May;63(5):1000-1010.
  55. Electroacu-puncture modulation of reflex hypertension in rats: role of cholecystokinin octapeptide. Am J Physiol Regul Integr Comp Physiol 2013 Aug;305(4):R404-413.
  56. Long-lasting reduction of blood pressure by electroacupuncture in patients with hypertension: randomized controlled trial. Med Acupunct 2015 Aug;27(4):253-266.
  57. Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology. Physiol Rep 2015 Aug;3(8).
  58. Blood pressure control with selective vagal nerve stimulation and minimal side effects. J Neural Eng 2014 Jun;11(3):036011.
  59. Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication. Hypertens Res 2016 Feb;39(2):79-87.
  60. Haemodynamic responses to selective vagal nerve stimulation under enalapril medication in rats. PLoS One 2016 Jan;11(1):e0147045.
  61. Frequency dependent effect of selective biphasic left vagus nerve stimulation on heart rate and arterial pressure. Signa Vitae 2012 Oct;7(2):63-68.
  62. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988 Jan;11(1):3-20.
  63. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014 Mar;28(3):150-156.
  64. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015 Jan;65(1):193-199.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.